secwatch.observer — SEC 8-K summary
======================================

Issuer:     Outlook Therapeutics, Inc. (OTLK)
CIK:        0001649989
Form:       8-K
Filed at:   2025-04-11T23:59:59+00:00
Accession:  0001558370-25-004726
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Outlook Therapeutics awards $237,500 retention bonus to CFO/Interim CEO Kenyon
------------------------------------------------------------------------------

- Cash retention bonus of $237,500 approved by Compensation Committee on April 9, 2025.
- Bonus payable December 31, 2025, contingent on Kenyon's continuous employment through that date.
- Kenyon declined option to receive stock options in lieu of cash; no election made.
- Upon a qualifying termination before Dec 31, 2025, bonus accelerated subject to release of claims.
- Retention bonus letter filed as Exhibit 10.1 with the 8-K.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649989/000155837025004726/0001558370-25-004726-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649989/000155837025004726/otlk-20250409x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-004726

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer